Morgan Stanley
TELO icon

Morgan Stanley’s Telomir Pharmaceuticals TELO Stock Holding History

Morgan Stanley’s Portfolio TELO Stock Details TELO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6 Buy
+5
New +$7 ﹤0.01% 8359
2025
Q4 		– Sell
-334
Closed -$464 – 8500
2025
Q3 		$464 Sell
334
-25,073
-99% -$37.8K ﹤0.01% 7505
2025
Q2 		$31.8K Sell
25,407
-3,616
-12% -$8.36K ﹤0.01% 6505
2025
Q1 		$93.7K Sell
29,023
-11,198
-28% -$48.9K ﹤0.01% 6041
2024
Q4 		$166K Buy
40,221
+28,767
+251% +$136K ﹤0.01% 5860
2024
Q3 		$73.5K Buy
11,454
+6,255
+120% +$30.5K ﹤0.01% 6106
2024
Q2 		$25K Buy
+5,199
New +$32.4K ﹤0.01% 6386

Other funds holding TELO

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $65.5B AUM 24.25% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
WIA
World Investment Advisors Santa Barbara, California $6.04B AUM 22.7% 1-Year Est. Return

Morgan Stanley's TELO Position: Q2 2026 in Review

Morgan Stanley opened a new position in Telomir Pharmaceuticals (TELO) in Q2 2026: 5 shares worth $6. The stake represents ﹤0.01% of the portfolio and ranks #8359 among its holdings. This is a return to the name: Morgan Stanley previously reported a position in TELO as recently as Q3 2025.

Morgan Stanley first reported a position in TELO in Q2 2024 and has held it in 7 quarters since. The position peaked at $166K in Q4 2024. 33 funds tracked by Wall St. Rank hold TELO as of Q2 2026.

  • Morgan Stanley held 5 shares of Telomir Pharmaceuticals worth $6 as of Q2 2026.
  • Telomir Pharmaceuticals was a new Morgan Stanley position in Q2 2026.
  • Telomir Pharmaceuticals made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #8359 holding.
  • Morgan Stanley first reported a position in Telomir Pharmaceuticals in Q2 2024 and has held it in 7 quarters since.
  • Morgan Stanley's Telomir Pharmaceuticals position peaked at $166K in Q4 2024.
  • 33 funds tracked by Wall St. Rank held Telomir Pharmaceuticals as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.